Cardiol Therapeutics Inc Class A (CRDL : TSX)
Common Stock
$1.75
CAD
+0.06 (3.55%)
Last updated: 2026-07-20
CRDL
Cardiol Therapeutics Inc Class A
WealthAwesomePerformance
1 Day
+3.55%
1 Week
+16.67%
1 Month
+16.28%
YTD
+28.68%
Key Statistics
Market Cap
$194.81M
52W High
$2.33
52W Low
$1.23
P/E Ratio
-
50 Day MA
$1.62
200 Day MA
$1.54
Beta
0.51
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 7/20/2026 | $1.76 | $1.81 | $1.65 | $1.75 | $1.75 | 136,772 |
| 7/17/2026 | $1.74 | $1.74 | $1.65 | $1.69 | $1.69 | 112,633 |
| 7/16/2026 | $1.57 | $1.81 | $1.51 | $1.74 | $1.74 | 177,653 |
| 7/15/2026 | $1.65 | $1.65 | $1.53 | $1.58 | $1.58 | 68,737 |
| 7/14/2026 | $1.50 | $1.69 | $1.50 | $1.63 | $1.63 | 185,764 |
| 7/13/2026 | $1.44 | $1.52 | $1.44 | $1.50 | $1.50 | 87,301 |
| 7/10/2026 | $1.44 | $1.44 | $1.37 | $1.44 | $1.44 | 52,066 |
| 7/9/2026 | $1.44 | $1.46 | $1.42 | $1.46 | $1.46 | 60,043 |
| 7/8/2026 | $1.46 | $1.46 | $1.40 | $1.44 | $1.44 | 35,068 |
| 7/7/2026 | $1.53 | $1.53 | $1.42 | $1.47 | $1.47 | 73,624 |
Analyst Price Targets
Based on analyst covering CRDL
Wall Street analysts forecast CRDL stock price to rise 242.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+242.9% Upside
Current Price
C$1.75
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
49.0%
Annualized
90-Day Vol
61.0%
Annualized
Trend (90d)
-25.6%
Annualized drift
90d Mean
C$1.60
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.70 | C$1.43 – C$2.01 |
| 60 trading days | C$1.65 | C$1.30 – C$2.09 |
| 90 trading days | C$1.60 | C$1.19 – C$2.14 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Cardiol Therapeutics Inc Class A
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-35.57M
- Profit Margin
- 0.00%
- ROE (TTM)
- -173.96%
- EPS (Diluted)
- -0.39
- Book Value
- 0.22
Classification
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Advertisement
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About CRDL
Articles Featuring CRDL.TO
Latest articles and analysis covering CRDL.TO
What's Going On With Cardiol Therapeutics Inc Class A Stock Monday?
Cardiol Therapeutics Inc Class A's stock has seen significant movement recently, driven by the publication of clinical trial results and upcoming investor engagements. As the company continues to navigate the complexities of the healthcare sector, investors should remain vigilant about both opportunities and risks.
Why Cardiol Therapeutics Inc Class A stock is sliding today
Cardiol Therapeutics Inc Class A's stock has taken a hit, closing down 2.87% at CA$1.69. Investors are left questioning the company's future amidst a lack of recent positive developments.
Why Cardiol Therapeutics Inc Class A stock is skyrocketing today
Cardiol Therapeutics Inc Class A has seen a remarkable 10.13% increase in its stock price, closing at CA$1.74. The rise is likely fueled by recent positive developments in the company's clinical research.
Why Cardiol Therapeutics Inc Class A stock is rising today
Cardiol Therapeutics Inc Class A has seen its stock price rise by 3.80%, reflecting positive investor sentiment driven by recent clinical advancements and successful financing efforts.
Why Cardiol Therapeutics Inc Class A stock is skyrocketing today
Cardiol Therapeutics Inc Class A (CRDL.TO) has gained 8.67% in the last trading session, closing at CA$1.63. This surge highlights investor optimism surrounding the company's clinical research efforts, particularly in the treatment of heart conditions.
Why Cardiol Therapeutics Inc Class A stock is skyrocketing today
Cardiol Therapeutics Inc Class A has experienced a significant stock price increase of 10.67% today, driven by positive investor sentiment surrounding its innovative cardiac treatments.
What's Going On With Cardiol Therapeutics Inc Class A Stock Tuesday?
Cardiol Therapeutics Inc Class A (CRDL.TO) has seen a 4.17% increase in its stock price today, as trading volume surged to more than double its 20-day average. This comes amid a backdrop of steady performance and no major news announcements this week.
Why Cardiol Therapeutics Inc Class A stock is rising today
Cardiol Therapeutics Inc Class A (CRDL.TO) has surged by 3.47% in today's trading session, closing at CA$1.49. This uptick is attributed to the company's recent financing activities aimed at supporting its clinical trials, particularly the MAVERIC Phase III trial.
Why Cardiol Therapeutics Inc Class A stock is sliding today
Cardiol Therapeutics Inc Class A experienced a significant drop in stock price, closing down 3.42% in the latest trading session. Investors may be concerned about the company's future prospects despite recent operational updates.
Why Cardiol Therapeutics Inc Class A stock is sliding today
Cardiol Therapeutics Inc Class A saw a significant drop in its stock price today, closing at CA$1.41. This decline of 4.08% raises questions about the company's future prospects amidst a lack of recent positive developments.
Why Cardiol Therapeutics Inc Class A stock is plummeting today
Cardiol Therapeutics Inc Class A saw its stock price drop by 5.88% in the latest trading session, closing at CA$1.44. This decline raises questions about the company's market position and future prospects.
Why Cardiol Therapeutics Inc Class A stock is gaining today
Cardiol Therapeutics Inc Class A is on the rise, with shares increasing by 1.63% to CA$1.55. This gain may signal investor optimism regarding the company's future prospects and recent operational updates.
Why Cardiol Therapeutics Inc Class A stock is tanking today
Cardiol Therapeutics Inc Class A (CRDL.TO) experienced a 0.65% drop in stock price today, closing at CA$1.53. This decline raises concerns about investor confidence amidst a lack of significant news to drive the stock's performance.
Why Cardiol Therapeutics Inc Class A stock is sliding today
Cardiol Therapeutics Inc Class A (CRDL.TO) faced a downturn in its stock price, closing at CA$1.47 after a 2.65% drop. Investors are left questioning the stability of this biotech firm amid a lack of recent positive news.
Why Cardiol Therapeutics Inc Class A stock is tanking today
Cardiol Therapeutics Inc Class A (CRDL.TO) faced a significant setback today, closing down 1.32% at CA$1.49. This decline raises questions about investor confidence in the company's future.
Why Cardiol Therapeutics Inc Class A stock is rising today
Cardiol Therapeutics Inc Class A (CRDL.TO) has experienced a 2.31% increase in its stock price, driven by investor optimism linked to its clinical advancements and upcoming presentations.
Why Cardiol Therapeutics Inc Class A stock is gaining today
Cardiol Therapeutics Inc Class A (CRDL.TO) is gaining traction in the market, with a 0.67% increase in its stock price. The company's active involvement in industry events and clinical trials is boosting investor confidence.
Why Cardiol Therapeutics Inc Class A stock is rising today
Cardiol Therapeutics Inc Class A has seen its stock rise by 4.08%, closing at CA$1.53. This increase is attributed to positive developments in the company's clinical trial programs and strategic initiatives.
Why Cardiol Therapeutics Inc Class A stock is sliding today
Cardiol Therapeutics Inc Class A saw its stock slide 3.18% today, closing at CA$1.52. With no significant news driving the decline, investors are left to ponder the implications for the company's future.
